|
|
| (2 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ticarcillin]] |
| {{Ticarcillin disodium}}
| |
| {{CMG}}; {{AE}} {{MM}}
| |
| ==Overview==
| |
| | |
| ==Category==
| |
| [[beta-lactam antibiotic]]s
| |
| | |
| ==US Brand Names==
| |
| TIMENTIN''''''<sup>®</sup>
| |
| | |
| ==FDA Package Insert==
| |
| '''[[Ticarcillin disodium description|Description]]'''
| |
| '''| [[Ticarcillin disodium clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Ticarcillin disodium microbiology|Microbiology]]'''
| |
| '''| [[Ticarcillin disodium indications and usage|Indications and Usage]]'''
| |
| '''| [[Ticarcillin disodium contraindications|Contraindications]]'''
| |
| '''| [[Ticarcillin disodium warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Ticarcillin disodium adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Ticarcillin disodium drug interactions|Drug Interactions]]'''
| |
| '''| [[Ticarcillin disodium overdosage|Overdosage]]'''
| |
| '''| [[Ticarcillin disodium dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Ticarcillin disodium how supplied|How Supplied]]'''
| |
| | |
| ==Mechanism of Action==
| |
| Ticarcillin disrupts bacterial cell wall development by inhibiting peptidoglycan synthesis and/or by interacting with penicillin‑binding proteins.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TIMENTIN (TICARCILLIN DISODIUM AND CLAVULANATE POTASSIUM) INJECTION, POWDER, FOR SOLUTION TIMENTIN (TICARCILLIN DISODIUM AND CLAVULANATE POTASSIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ffe8c3f-9694-4029-fca3-1b19c5cc2f93#nlm34089-3 | publisher = | date = | accessdate}}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Antibiotics]]
| |
| [[Category:Wikinfect]]
| |